NCT05231785 - A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

March 28, 2029

Study Completion Date

March 28, 2029

Conditions

Early-Onset Alzheimer Disease

Interventions

DRUG

ALN-APP

ALN-APP will be administered intrathecally (IT)

DRUG

Placebo

Placebo will be administered IT

Trial Locations (8)

RECRUITING

Clinical Trial Site, Indianapolis

WITHDRAWN

Clinical Trial Site, San Diego

RECRUITING

Clinical Trial Site, San Diego

RECRUITING

Clinical Trial Site, Toronto

RECRUITING

Clinical Trial Site, Montreal

RECRUITING

Clinical Trial Site, Amsterdam

RECRUITING

Clinical Trial Site, London

RECRUITING

Clinical Trial Site, Sheffield